Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anselamimab - Caelum Biosciences

Drug Profile

Anselamimab - Caelum Biosciences

Alternative Names: 11-1F4; CAEL-101; Ch mAb 11-1F4; Chimeric fibril reactive monoclonal antibody 11-1F4 -Caelum Biosciences; Fibril-reactive monoclonal antibody 11-1F4; mAb 11-1F4

Latest Information Update: 22 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Columbia University
  • Developer Alexion AstraZeneca Rare Disease; Caelum Biosciences
  • Class Monoclonal antibodies
  • Mechanism of Action Serum amyloid A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloidosis; Amyloid light-chain amyloidosis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Amyloid light-chain amyloidosis

Most Recent Events

  • 09 Dec 2023 Adverse events data from phase II clinical trials in Amyloid light-chain amyloidosis were presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
  • 14 Nov 2023 Alexion Pharmaceuticals completes a phase II trial in Amyloid light-chain amyloidosis (Combination therapy, Treatment-experienced) in USA (IV) (NCT04304144)
  • 08 Jun 2023 Efficacy and adverse event data from a phase II/III trial in Amyloid light chain amyloidosis presented at 28th Congress of the European Haematology Association (EHA-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top